Anthony Mato, MD, shares findings from a phase I/II trial evaluating LOXO-305 in patients with heavily pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Recent Articles
Loss of STK11/LKB1 Drives Progression to Leukemia in Myeloproliferative Neoplasms
Results from a CRISPR/Cas9 screening study suggest that loss of STK11 promotes progression to leukemia in patients with myeloproliferative neoplasms (MPNs), according to findings...
FLAG-IDA Plus Venetoclax Associated With High Response Rates in Acute Myeloid Leukemia
Adding venetoclax to fludarabine, cytarabine, granulocyte-colony stimulating factor, and idarubucin (FLAG-IDA) translated into high response rates across subgroups of patients with acute myeloid leukemia...
Examining Immune Response in Patients with Hematologic Malignancy After COVID-19 Infection
Patients with a history of a hematologic malignancy who survive COVID-19 infection have similar immune responses against the virus following infection compared with people...
CARTITUDE-1: Myeloma CAR T-Cell Therapy Produces Deep and Durable Responses
A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and...
BTK Inhibitor LOXO-305 Shows Promise in Previously Treated Mantle Cell Lymphoma
In the phase I/II BRUIN trial that included patients with previously treated B-cell malignancies – particularly mantle cell lymphoma (MCL) – treatment with the...
Current Issue
Mid-January 2021 Annual Meeting Edition
This issue features highlights from the 2020 ASH Annual Meeting, a look at doctor-patient gifting customs around the world, and more.